Login / Signup

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.

Shivaani KummarLin ShenDavid S HongRay McDermottVicki L KeedyMichela CasanovaGeorge D DemetriAfshin DowlatiSoledad Gallego MelcónUlrik N LassenSerge LeyvrazTianshu LiuVictor MorenoJyoti PatelTejas PatilAtrayee Basu MallickNuno SousaMakoto TaharaDavid S ZieglerRicarda NorenbergPierre ArvisNicoletta BregaAlexander DrilonDaniel S W Tan
Published in: Cancer (2023)
Tropomyosin receptor kinase (TRK) fusion proteins result from translocations involving the NTRK gene and cause cancer in a range of tumor types. Larotrectinib is an agent that specifically targets TRK fusion proteins and is approved for the treatment of patients with TRK fusion cancer. This study looked at how well larotrectinib worked in adult patients with sarcomas caused by TRK fusion proteins. Over half of patients had a durable response to larotrectinib, with no unexpected side effects. These results show that larotrectinib is safe and effective in adult patients with TRK fusion sarcomas.
Keyphrases
  • papillary thyroid
  • high grade
  • end stage renal disease
  • ejection fraction
  • prognostic factors
  • squamous cell carcinoma
  • squamous cell
  • genome wide
  • protein kinase
  • dna methylation
  • binding protein